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Abstract. This review article is an analysis of the most recent published scientific articles about myxomatous valve degeneration (mvd) 
and was conducted over a five month period. The aim of this review is to consolidate information about the most recent medical deve-
lopments in regards to myxomatous degeneration in the mitral valve. The authors of this article reached a consensus on both the deve-
lopment of the disease and the most effective type of diagnosis and treatment that is available today. Myxomatous valve degeneration is 
the most common heart disease in the canine population. It is identified by a loss of mechanical integrity in the heart due to structural 
changes in the valvular components. Degenerative changes occur due to an accumulation of mucopolysaccharides in the leaflets and 
chordae which affect the proper operation of the valve apparatus. This is caused by faulty coaptation of the leaflets, resulting in mitral 
or tricuspid regurgitation, dilated ventricles and annuli, which are lesions that eventually cause the rupture of the chordae tendineae, 
leading to complications or possibly death. Due to the gradual progression of the disease and the presence or absence of clinical signs, 
it is very important that veterinarians accurately diagnose and follow-up on these patients in order to achieve stabilization and provide 
a suitable prognosis and  treatment plan. The current ideal treatment of the disease is a low-sodium diet, administration of the ace in-
hibitor (angiotensin-converting-enzyme inhibitor) spironolactone and a diuretic in order to reduce the presence of pulmonary edema 
and avoid the progression of the disease to congestive heart failure.
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Degeneração valvar mixomatosa. Um olhar nos 
últimos avanços em todos os aspectos da doença
Resumo. Este artigo de revisão se realizou durante um período de cin-
co meses. Incluíram-se, neste, os últimos avanços publicados em artigos 
científicos. Conseguiu-se realizar um consenso quanto ao desenvolvi-
mento da doença, ao tipo de diagnóstico mais adequado e ao tratamento 
que melhores resultados está mostrando na atualidade. O objetivo desta 
revisão foi conhecer as últimas atualizações sobre a degeneração valvu-
lar mixomatosa. A degeneração valvar mixomatosa é a doença cardíaca 
mais comum na população canina, na qual há uma perda da integridade 
mecânica devido a mudanças estruturais nos componentes valvulares. 
As mudanças se devem a uma acumulação de mucopolisacáridos nas 
cordas tendíneas e nas valvas as quais iniciam com falhas na coaptação 
das valvas gerando uma regurgitação mitral ou tricuspidiana, dilatação 
dos ventrículos e do anel valvular, levando a complicações ou morte do 
paciente. Devido ao progresso gradual das lesões na doença e à mani-
festação ou não de signos clínicos, o diagnóstico exato e seguimento 
apropriado desses pacientes é de grande importância para os médicos 
veterinários com o objetivo de prognosticar e instaurar o tratamento 
adequado. O melhor tratamento na atualidade para a doença consiste 
em uma dieta baixa em sódio, administração de um Inibidor da Enzima 
Convertidora de Angiotensima (ieca), espironolactona e um diurético 
a fim de diminuir a presença de signos associados a edema pulmonar e 
evitar o progresso desta a uma insuficiência cardíaca congestiva.
Palavras-chave: válvulas av, canino, coração, degeneração mixomatosa, 
tratamento.
Degeneración valvular mixomatosa. Una mirada a los 
últimos avances en todos los aspectos de la enfermedad
Resumen. Este artículo de revisión se realizó durante un periodo de cin-
co meses, en el que se incluyeron los últimos avances publicados en ar-
tículos científicos. Se logró realizar un consenso en cuanto al desarrollo 
de la enfermedad, el tipo de diagnóstico más adecuado y el tratamiento 
que mejores resultados está mostrando en la actualidad. El objetivo de 
esta revisión fue conocer las últimas actualizaciones acerca de la degene-
ración valvular mixomatosa. La degeneración valvular mixomatosa es la 
enfermedad cardiaca más común en la población canina, en la cual hay 
una pérdida de la integridad mecánica debido a cambios estructurales en 
los componentes valvulares. Los cambios se deben a una acumulación de 
mucopolisacáridos en las cuerdas tendinosas y las valvas, lo cual inicia 
con fallas en la coaptación de las valvas, generando una regurgitación 
mitral o tricuspidiana, dilatación de los ventrículos y del anillo valvu-
lar, llevando a complicaciones o muerte del paciente. Debido al progreso 
gradual de las lesiones en la enfermedad y a la manifestación o no de 
signos clínicos, el diagnóstico exacto y seguimiento apropiado de estos 
pacientes es de gran importancia para los médicos veterinarios con el 
fin de pronosticar e instaurar el tratamiento adecuado. El mejor trata-
miento en la actualidad para la enfermedad consiste en una dieta baja en 
sodio, administración de un ieca (Inhibidor de la Enzima Convertidora 
de Angiotensina), espironolactona y un diurético con el fin de disminuir 
la presencia de signos asociados al edema pulmonar y evitar el progreso 
de esta a una insuficiencia cardiaca congestiva. 
Palabras clave: válvulas av, canino, corazón, degeneración mixomatosa, 
tratamiento. 
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Introduction1
Myxomatous thickening and poor coaptation of the 
av valves are major causes of morbidity and mortality 
in dogs. [1] This condition is known as myxomatous 
valve degeneration (mvd), a heart disease commonly 
acquired by small dog breeds during adulthood. [2] 
The disease does not have a defined etiology, and for 
this reason several hypotheses have arisen about the 
ways in which genetics and hemodynamic and endog-
enous factors may affect the disease. [3-5] mvd is the 
most common cause of heart failure in dogs and is con-
sidered to comprise 70-80% of heart-related diseases 
affecting this species. [6-7] Chronic valvular heart dis-
ease most often affects the mitral valve, but approxi-
mately 30% of cases involve the tricuspid valve. There 
is a particularly high incidence of the disease in cer-
tain breeds such as the Cavalier King Charles Spaniel 
(ckcs), in which it can be present in 90% of cases. [8] 
It has been reported that around 50% of ckcs that have 
a secondary murmur, degenerative lesions and mitral 
regurgitation at the age of 5-6 years tend to progress 
faster in the disease than other breeds. [7] mvd is also 
considered an important clinical event since it has 
similarities with the pathophysiology of humans [9] 
and is therefore recognized as a natural model for the 
human disease. [10] According to the American Heart 
Association (aha), in 2003 cardiac valvular disease 
directly caused around 19,989 deaths and contributed 
to 42,590 deaths. [11] This disease is characterized by 
the loss of mechanical integrity in the valves, failure of 
proper coaptation of the leaflets during ventricular sys-
tole and regurgitation of blood throughout the leaflets. 
[12] The loss of mechanical integrity is the result of the 
destruction of the fibrous layer, expansion of connec-
tive tissue in the spongiosa layer and an excessive ac-
cumulation of glycosaminoglycans [9], thus generating 
an audible murmur during auscultation. 
mvd typically progresses slowly and becomes se-
vere over the years. This progression can lead to conges-
tive heart failure (chf) and due to the variable disease 
pathology can also lead to sudden death. [13, 14] The 
aim of this review is to further understand the latest de-
velopments of myxomatous degeneration in order to 
prevent these complications.
1 This article is the result of a research project of the National Comi-
ttee for Research Development (Conadi according to its initials in Span-
ish) at Universidad Cooperativa de Colombia.
Diagnosis
Although some dogs with mvd remain asymptomatic 
for several years or even for their entire lives, severe 
complications can occur that lead to the death of the 
patient. For this reason the exact diagnosis and moni-
toring of the progression in a timely manner is of criti-
cal clinical interest in order to be able to predict the 
risk of decompensation, determine a prognosis and 
adopt an appropriate medical prescription. 
An important assessment in the clinical examina-
tion of patients is auscultation, through which we can 
detect and classify a heart murmur, depending on its 
intensity and the presence of precordial shock. There 
is evidence that the intensity of the murmur detected 
during auscultation depends on the degree of regur-
gitation and is prognostic for the progression of heart 
failure. Therefore, the degree of the murmur can be a 
useful indicator for the diagnosis of mvd. [13] How-
ever, it is possible for mvd to manifest itself without 
the specific presence of this sign. The severity of heart 
murmur is usually graded out of six by auscultation ac-
cording to its intensity and the presence of a precordial 
thrill. There is evidence that the intensity of the mur-
mur detected by auscultation is dependent on the de-
gree of mitral regurgitation and is prognostic for the 
progression of heart failure. Thus, the grade of murmur 
would appear to be an adequate diagnostic indicator of 
the severity of mitral valve disease. This indicates that 
cardiac degeneration occurs undetected for a long pe-
riod of time and therefore the presence of a murmur 
should always be assessed by echocardiography to de-
termine the remodeling of the ventricles and atria. [15] 
Transthoracic echocardiographic evaluation is 
now considered the method of choice for non-invasive 
diagnoses in detecting valvular lesions. With this meth-
od, we can assess the severity of regurgitation, the im-
pact on cardiac remodeling, myocardial functioning, 
the filling pressure of the ventricles and the pulmonary 
artery pressure. Even though transthoracic echocardio-
graphic evaluation is considered the main diagnostic 
tool, it has its limitations because of the way the pa-
tient is handled and the extent of knowledge necessary 
to use the equipment correctly. [16] M-mode echocar-
diography views are obtained from a right parasternal 
position and are used to obtain left ventricular and atri-
al dimensions, using a short axis to measure the rate of 
the aorta and left atrium. [17] Myxomatous mitral valve 
disease can be diagnosed by identification of charac-
teristic valve leaflet abnormalities (thickening and/or 
prolapse) and evidence of flow of regurgitation across 
the mitral valve detected by color-flow Doppler. [18] 
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The tissue Doppler imaging (tdi) technique has been 
shown to be more sensitive than conventional echocar-
diography in detecting systolic and diastolic myocardi-
al alterations in humans as well as in experimental or 
spontaneous heart diseases in animals, as demonstrat-
ed by our research group in a dog model of dilated car-
diomyopathy. [figure 1] One important tdi application 
is the assessment of diastolic function, which may be 
impaired in aged dogs with mvd. [19] 
One of the most important methods used with ra-
diographic evidence is the measurement of the verte-
bral heart size. [21] Electrocardiographic findings are 
usually nonspecific, showing a P wave and wide qrs 
secondary to enlargement of the left atrium and the left 
ventricle (lv). [20]
Structure and function 
av valves are a unique tissue exposed to a complex 
mechanical environment that consists of two leaflets: 
the anterior (septal) and the posterior (parietal) with 
unique morphological characteristics. [22] The cellular 
component of the cardiac valves consists mainly of en-
dothelial, interstitial and smooth muscle cells, of which 
the interstitial cells play a critical role in maintaining 
valvular competence and counteracting biomechanical 
problems. [23] This means they are an active and dy-
namic component of the valves, which allows them to 
remodel in response to stressors. [24] These structures 
are subjected to four mechanical forces in the valve: the 
opening (flexure), the allowing of the passage of blood 
(shear), the closure (flexure), and the prevention of 
blood reflux (tension and compression). [10]
The anterior leaflet area is larger, has less chordae 
and a large number of elastic components. The poste-
rior leaflet is smaller and thinner with a large number 
of chordae tendineae that provide mechanical support 
and compensate for its delicate structure. Both leaflets 
show a soft tissue biomechanical response to stretching.
The annular region is more rigid than the free 
edge and is less flexible than the atrialis or ventricular-
is. These properties correspond to the microstructure 
of each area, which is influenced by the presence or ab-
sence of chordae tendineae.
Chordae tendineae are classified into three sub-
types, based on location and function: strut, primary 
and secondary. The chordae tendineae modulate stress 
transmission to the leaflets, which is evidenced by the 
heterogeneity of mechanical properties and microstruc-
ture of the insertion of the strings in the leaflet. [22]
The functions of the mitral and tricuspid appara-
tus are to keep the valve open during diastole to allow 
proper filling of the ventricles and to close smoothly 
without allowing blood backflow during ventricular 
systole. [27] In order for this heart valve to work prop-
erly, many related structures must also function cor-
rectly, such as the av ring, the av leaflets, the chordae 
that hold them, the papillary muscles and the myocar-
dium. [28]
Figure 1. Doppler imaging showing mitral regurgitation
Source: elaborated by the authors
Figure 2. Radiography of a dog with heart failure showing peri-
hilar edema
Source: elaborated by the authors
In radiographic cardiomegaly, evidence of the dis-
ease is usually detected by an enlarged left side of the 
heart. The left atrium (la) is enlarged and compressed 
or the left main bronchus is elevated. Pulmonary ve-
nous congestion is commonly observed with pulmo-
nary edema, especially in the perihilar area. [20]
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Pathology
mvd most commonly affects atrioventricular valves, but 
the disease can affect all cardiac valves. Myxomatous 
changes have been reported in mitral valve disorders 
in 62% of dogs, with mitral and tricuspid comprising 
32.5% and tricuspid 1.3%. [28]
The pathology of myxomatous valves in humans and 
in dogs includes increased cellularity, disorganization 
Figure 3. Cardiac valve anatomy 
Source: Connell [25]
Atrialis: endocardium, continuation of atrial.
Spongiosa: a rare collection of fibers and bundles of collagen, with some 
elastic fibers with mucopolysaccharides.
Fibrous: a dense layer of collagen fibers.
Ventricularis: endocardium, continuous with the ventricular lining [26] 
Figure 4. From the histological point of view, we can divide the 
normal mitral valve into 4 layers, from the atrium to the ventricle. 
Hematoxilin-eosin 10x 
Source: Mucha [26]
Figure 5. A collagen decrease in a canine with a volume overload caused by mitral regurgitation, B collagen in a canine with a normal 
heart and C increased collagen in a canine with pressure overload caused by experimental aortic stenosis
Source: Dillon [30]
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of valve structure as well as transdifferentiation of 
valve endothelial cells and valve interstitial cells. [29] 
In mvd we see the development of degenerative con-
nective tissue, which manifests itself in excessive stro-
mal destruction and alteration of the valve with loss 
of collagen organization and accumulation of proteo-
glycans and glycosaminoglycans in the leaflets and 
chordae. [25]
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A study by Hadian et al. showed a 10% reduction 
in total collagen and a 20% reduction in fibrillar colla-
gen content in the myxomatous areas of canine valves 
with mild to moderate mvd. [31]
These alterations are known as mucopolysacchari-
dioses (mpss), which are characterized by a functional 
deficiency caused by a genetic mutation of a lysosomal 
enzyme that acts on the sequential catabolism of glyco-
saminoglycans. It has been reported that all mps syn-
dromes affect the heart and that an absence of heparan 
sulfate and dermatan sulfate is a common feature in 
mps I, II, and VI. [32]
Histopathologically mvd is characterized by the 
expansion of the pars spongiosa that invades and pro-
duces a focal disruption of the fibrous pars, generating 
changes such as hyalinization and dilation, fragmen-
tation of the bundles and in severe cases isolated frag-
ments that can be observed in the fibrous layer. [26]
surface of the leaflets. [25] A roughened area of the 
valve on the side where the nodules connect with the 
ventricular chordae is predisposed to suffer myxoma-
tous degeneration. [25]
Risk factors associated with the progression of the 
disease  or death in dogs with mvd include age, gender, 
intensity of the heart murmur, degree of valve prolapse, 
degree of mitral regurgitation (mr), degree of left atrial 
enlargement, severity of eccentric hypertrophy, rupture 
of chordae tendineae and increasing concentrations of 
natriuretic peptides. [34]
mvd lesions occur gradually and do not show 
clinical signs at the beginning of the first structural 
changes. [35] The progression of the disease which 
occurs leads to inadequate coaptation of the leaflets 
by increasing the blood flow in the atrium, known as 
mitral regurgitation (mr). This causes an increase in 
the lv volume overload and as a result leads to an in-
crease in cardiac oxygen demand, [36] causing dila-
tation of the lv and the mitral ring accompanied by 
ejection injuries and rupture of the chordae. [35] Pa-
tients with acute mr generally show high pulmonary 
venous pressure, while those with chronic mr shown 
an enlarged ventrical with decreased pulmonary vein 
pressure. [35] 
As a result of these injuries we find mitral systolic 
murmurs [25], which generate chf by reaching the left 
and then the right side of the heart due to pulmonary 
hypertension. [16] This sign is taken as the pressure in-
crease of the la and a vasoconstrictive reaction of the 
pulmonary artery associated with acute or chronic hy-
poxia. [37] The insufficiency of the tricuspid valve can 
also occur in dogs, leading to heart failure. This valve 
malfunction is associated with focal or diffuse thick-
ening of the valves and reduced performance of the 
chordae and papillary muscles, causing regurgitation 
in the atrium that finally leads to right atrium and ven-
tricle dilatation. The clinical signs related to right heart 
failure are accumulation of fluid in the abdominal and 
chest cavity, swelling of the limbs, discomfort and diffi-
culty finding a comfortable position to rest, lack of ap-
petite, weight loss and lethargy.
chf begins when the body is unable to provide the 
required oxygen to different tissues and cells trigger a 
response mechanism. The first response is the activa-
tion of receptors β in the aorta because of changes in 
pressure. As days go by these receptors are saturated 
and several hormones (endothelin, aldosterone, atrial 
natriuretic peptide and renine) are released in an at-
tempt to correct the problem. These receptors retain 
Figure 6. Valvar contact area, showing a severe infiltration of 
mpss (blue) separately and invading the collagen structure (pur-
ple). Alcian Blue / pas. 40x 
Source: Mucha [26]
Matrix metalloproteinases (mmps) and the tis-
sue inhibitors of metalloproteinases (timps) appear to 
play an important role in maintaining a normal physi-
ological extracellular matrix, which is affected by mvd. 
mmps are a family of proteolytic enzymes that are in-
volved in the protein degradation in the extracellular 
matrix and play an important role in remodeling. It has 
been shown that in a canine mitral valve with advanced 
mvd, the expression of mmps decreases and timps in-
creases. [33] Early pathological lesions are nodules 
usually located in the zone of apposition on the atrial 
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Figure 7. Flow chart showing the series of events caused by stretch. Hypothetical scheme of stretch induced by hypertension, heart 
failure and possibly extreme endurance exercise leadinh to calcium overload, activation of the renin-angoptensin-aldosterone system 
(raas) and release of different factors, resulting in structural remodelling and finally in af
Source: De Jong et al. [38]
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the fluid for the purpose of increasing blood volume 
and output of blood and oxygen to the heart. For sev-
eral months these compensation mechanisms help the 
situation, but eventually increased fluid retention be-
comes detrimental to the capillaries in the lungs, abdo-
men and other tissues. [38]
The most important sign of failure in the left side 
of the heart is pulmonary edema and in the right is asci-
tes and pleural and pericardial spills. [39] When chf is 
secondary to mvd it can cause sudden death due to ar-
rhythmias, hypoxemia, pulmonary embolism and mul-
tiple organ failure. [27]
Mechanical stress contributes to phenotypic 
changes in the mitral valve that undergoes degenera-
tion, suggesting that these factors contribute to the de-
velopment of mvd in canines. This is why scanning is 
required not only in vivo but in vitro, to allow for a spe-
cific analysis of the signaling mechanisms of the dis-
ease. [40]
Clinical signs
Clinical signs of dogs with mvd include manifestations 
of chf on the left side of the heart, such as exercise 
intolerance, cough, dyspnea and syncope. The cough 
is usually associated with the elevation of the left main 
bronchus due to enlargement of the la. It is described 
as a dry cough, occurring after exercise, excitement 
or in the evening. Syncope may be related to an inad-
equate flow, pulmonary hypertension or cardiac ar-
rhythmia. [20]
Clasification of chf (acvim)
The challenge for veterinarians facing patients with 
this disease is to establish a proper diagnosis by recog-
nizing the progressive stage of the disease in order to 
treat the patient appropriately. [41]
There are several ways to categorize heart disease in 
dogs, but the latest has been published by the American 
College of Veterinary Internal Medicine (acvim). The 
acvim uses a classification from A to D. Category A 
dogs do not have heart disease but are at risk, such as 
the Cavalier King Charles Spaniel and Poodle. Catego-
ry B dogs have mild heart disease, both without cardiac 
remodeling (B1) and with cardiac remodeling (B2), but 
with no evidence of present or historical chf. Category 
C dogs have signs of heart failure and are either hospi-
talized (C1) or treated at home (C2). Category D dogs 
are terminal with refractory symptoms of heart failure, 
either treated in a hospital (D1) or at home (D2). The 
classification of patients can change their category ac-
cording to decompensation, disease progression and 
treatment. [42]
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Treatment
One of the compensatory mechanisms in patients with 
mvd is the activation of the renin angiotensin aldos-
terone system (raas), which is favorable in cardiac 
patients, since the action of angiotensin II leads to an 
increase in vascular and arterial pressure. [43] This 
mechanism becomes detrimental after a prolonged pe-
riod in these patients because it increases the volume 
of regurgitation  and causes eccentric hypertrophy. Be-
cause of this, the suppression of this system is of great 
importance, which is why treatment should start with 
an angiotensin-converting enzyme inhibitor (ace in-
hibitor), which blocks the production of angiotensin 
II, thereby increasing levels of bradykinin and impro-
ving the functioning of the left ventricle and skeletal 
muscle circulation. [44] 
Conventional treatment for heart failure includes 
ace inhibitors and furosemide. However, ace inhibi-
tors are poor suppressors of aldosterone secretion and 
furosemide increases the secretion of this hormone, 
which in turn increases extracellular fluid volume, put-
ting more stress on the heart. This has a direct negative 
effect on the heart muscle and vasculature. For this rea-
son spironolactone is added to the conventional treat-
ment as a selective inhibitor of aldosterone [38], which 
acts on the distal tubule to increase sodium and water 
excretion and decrease potassium excretion. [45] An-
other of its virtues is to decrease cardiac fibrosis and 
norepinephrine release. [46]
Patients in stage A are asymptomatic and do not 
require drug therapy because the physiological com-
pensation does not allow for the presence of clinical 
signs. Treatment should be set up in patients with stage 
B in which the sympathetic system has been altered 
and the activation of rass has occurred, increasing the 
pressure and volume with sodium retention secondary 
to the vasoconstriction caused by angiotensin II. Over 
time this system generates changes in the myocardium 
that should be prevented by an ace inhibitor such as 
enalapril and benazepril, as currently accompanied by 
potassium savers such as spironolactone that in pro-
longed low doses prevent cardiac remodeling, The use 
of Pimobendan is also recommended to potentiate the 
inhibition of cardiac remodeling in patients with this 
pathology. Patients with stage C progression demon-
strate critical clinical signs such as pulmonary edema 
due to mitral valve insufficiency, for which it is useful 
to use furosemide.
In a recent study the administration of 2 mg/kg 
of spironolactone for a period of 15 months success-
fully reduced morbidity and mortality by 55% in pa-
tients with heart disease compared to those receiving 
conventional therapy with ace inhibitors such as fu-
rosemide and digoxin. [44] Since the progression of 
mvd can in fact cause chf, the administration of spi-
ronolactone must be accompanied by an ace inhibitor 
and a loop diuretic, which have been of great impor-
tance for the treatment of chf in humans and veteri-
nary patients because of their ability to reduce clinical 
signs associated with pulmonary congestion and pul-
monary edema. In veterinary patients furosemide has 
been the loop diuretic of choice, but according to stud-
ies of dogs receiving high doses of furosemide (4-8 mg\
kg), they continue suffering from congestion. Poor per-
formance of furosemide is reflected not only in the pro-
gression of the disease but also in diuretic resistance. 
In humans with advanced heart disease, diuretic resis-
tance is well described in the literature. [47] There are 
studies of a loop diuretic called torasemide being used 
in human patients with chf that acts upon the neph-
ron ascending loop of Henle, promoting the excretion 
of sodium, chlorine and water. This diuretic has a high 
bioavailability in humans, a long half-life and duration 
of action greater than that of furosemide, resulting in a 
stronger and more effective diuresis. It further demon-
strated a significant reduction in morbidity and cardiac 
death. The superiority of torasemida over furosemide 
is due to its antifibrotic effects on the myocardium that 
appear to be mediated by the antagonism of aldoste-
rone in a way similar to that of spironolactone. [48]
Since sodium retention is a major contributor to 
congestion, the restriction of electrolytes in the diet 
has been used in the management of heart failure. It 
has recently become clear than the extreme restriction 
Figure 8. acvim Cardiac Disease Classification 
Source: Atkins [42]
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of sodium activates raas and may contribute to renal 
dysfunction, particularly when ace inhibitors are used. 
For this reason the use of moderate-salt diets with 22% 
sodium for kidney patients are recommended in early 
stages of heart failure, as well as restriction diets with 
10% sodium for patients with refractory therapy. [49]
Valve repair or replacement through open heart 
surgery with the use of cardiopulmonary bypass has 
also been reported in dogs with mvd. However, this 
treatment is expensive, not widely available, and has 
limitations depending on the size of the patient. Surgi-
cal intervention is focused on reducing the circumfer-
ence of the mitral annulus in order to decrease the rm 
and reduce mvd progression. [30, 50]
Conclusions
mvd is a disease of great clinical interest because it is 
an acquired heart disease that affects a large percentage 
of the dog population and has great pathophysiological 
similarity to humans. Due to the nature of the progres-
sion of the disease, which often is nearly undetectable, 
constant revision by the veterinarian is important to be 
able to diagnose the stage of the disease and to stabilize 
and treat patients appropriately. A better understan-
ding of the pathophysiology of myxomatous valvular 
degeneration would help prevent or treat existing le-
sions and prevent progression of the disease to chf.
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